Stan Messner, MD
Family Medicine · Wichita, KSNPI 1780792804
Payments from drug & device makers
Across 378 payments — averaging $14.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$858
- AstraZeneca$669
- Amgen$564
- AbbVie$549
- Novo Nordisk$430
- Boehringer Ingelheim$208
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,297100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 85 | $858 |
| AstraZeneca | 20 | $669 |
| Amgen | 39 | $564 |
| AbbVie(2 entities) | 39 | $549 |
| Novo Nordisk | 38 | $430 |
| Boehringer Ingelheim | 15 | $208 |
| Medtronic | 6 | $191 |
| Amarin Pharma, Inc. | 14 | $178 |
| Johnson & Johnson | 16 | $178 |
| Lilly USA, LLC | 9 | $122 |
| Eisai Inc. | 8 | $121 |
| Biohaven Pharmaceuticals, Inc. | 20 | $118 |
| Sumitomo Pharma America, Inc. | 7 | $117 |
| Novartis | 5 | $96 |
| Abbott | 6 | $88 |
| Grifols USA, LLC | 3 | $75 |
| Daiichi Sankyo Inc. | 5 | $64 |
| Astellas Pharma US Inc | 5 | $63 |
| Dexcom, Inc. | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Merck | 4 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Cranial Technologies, Inc | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| GSK | 3 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $36 |
| Nevro Corp. | 1 | $34 |
| Pacira Therapeutics, Inc. | 2 | $29 |
| Exact Sciences | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Micro-tech Endoscopy USA, Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 2 | $23 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,297 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $43,079 |
| FarxigaDapagliflozin Propanediol | 44 | $29,361 |
| EliquisApixaban | 44 | $25,665 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $19,287 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $16,666 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $14,324 |
| JanuviaSitagliptin Phosphate | 11 | $14,094 |
| XareltoRivaroxaban | 20 | $13,973 |
| MyrbetriqMirabegron | 25 | $11,255 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $10,802 |
| JardianceEmpagliflozin | 13 | $8,090 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $7,212 |
| Cefdinir | 269 | $4,071 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,505 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $1,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $430 | $43,07937 claims |
| AstraZenecaFarxiga, Symbicort | $669 | $32,86655 claims |
| PfizerEliquis | $858 | $25,66544 claims |
| GSKTrelegy Ellipta | $37 | $16,66626 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $208 | $15,30225 claims |
| MerckJanuvia | $47 | $14,09411 claims |
| Johnson & JohnsonXarelto | $178 | $13,97320 claims |
| Astellas Pharma US IncMyrbetriq | $63 | $11,25525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Wichita
- Terry PolingWichita$24.2M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Brandon AllemanWichita$3M
- Tracy KleinWichita$2.7M
- William SimonWichita$1.1M
- Tana GoeringWichita$1.1M
- Gregory LakinWichita$897K
- Timothy KoehlerWichita$675K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.